about
Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT)Real-world research and its importance in respiratory medicineInteractions between HIV infection and chronic obstructive pulmonary disease: Clinical and epidemiological aspectsComparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study.Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting.Impact of current cough on health-related quality of life in patients with COPD.A review of national guidelines for management of COPD in EuropeImproving the Management of COPD in WomenAssociation between occupational exposure and the clinical characteristics of COPDAdd-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler[Mucoregulators in acute bronchitis syndromes: focus on use by general practitioners and data from the literature].Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.[French data from the Continuing to Confront COPD (C2C) survey].Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.Atmospheric pressure influences the risk of pneumothorax: beware of the storm!Tiotropium might improve survival in subjects with COPD at high risk of mortality.Recent changes: pulmonary medicine.Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment.Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancerMultidimensional analyses to assess the relations between treatment choices by physicians and patients' characteristics: the example of COPD.Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPDObservational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study.Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortalityA clinical in-hospital prognostic score for acute exacerbations of COPD.InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients--the LIAISON study protocolReal-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study.Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study.Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness.High quality standards for a large-scale prospective population-based observational cohort: ConstancesClinical practice guidelines: medical follow-up of patients with asthma--adults and adolescents.Body Mass Index and Total Psoas Area Affect Outcomes in Patients Undergoing Pneumonectomy for Cancer.Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study.Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infectionsRole of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapyRelation between inflammation and symptoms in asthma.Rising total costs and mortality rates associated with admissions due to COPD exacerbations.Impact of gender on COPD expression in a real-life cohort.Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities.
P50
Q26751471-B221E8D0-5A99-4B49-B78F-12A1086503EFQ26797460-19F63D33-3B99-4542-B63E-51E09D5B3C20Q26850063-859CF216-0E86-4B8A-96EA-821B7FA776A7Q27309809-66D15003-C432-481D-A707-72FE0547E3B0Q27334822-DC5148C0-0C2A-4233-8E25-C980A75F482CQ27338986-194FD4BA-72B6-4E3A-9BA2-E003B93C29DDQ28072014-5A6F34C5-18DC-4D04-A2D3-008DF2931999Q28073791-DF2951C3-F442-40A3-98BD-736CA164CE79Q28390487-6500AFD7-9982-4E73-89E8-0D05C21713C9Q28596628-30F385BC-C63D-4990-A431-AFCCBDBD59F9Q30918574-0D7AE3BD-AB64-41C6-BF0B-0C53B3F35879Q30955660-FAB26041-027E-4EB7-A03A-F03EF3CC3447Q31115222-4B568C8E-2614-48C4-B17A-E5E640728637Q33345319-95501A5B-5B84-46A8-970F-AB911A26328FQ33436979-C0DB5F9F-0C0C-477F-8066-FC9334D9E7F8Q33769268-62956AC0-89CC-49AE-9903-DFC49CD6AA43Q33793338-58DB9F6F-E2A7-4FA5-9FC7-047EC3D0115BQ33883565-A7FA849D-6DBA-466B-9628-95790C52112BQ34215504-4754CA0B-1E55-4FEA-90DB-144C3E9CB02AQ34367792-9A05AE98-55DA-4625-9125-BEB3548AEC4DQ34394322-CCD0330F-199E-410C-942E-7705A62383E1Q34451879-C0D94F20-5812-4457-BD48-34A1409C377CQ34510698-0DB23FCC-DBDE-47D2-B9BB-843C9139D6A6Q34571705-7669E4C3-25E6-45D0-9DE6-B856A6BFB500Q34636556-6A458E9A-4C1B-479F-921E-3A881D25D493Q35138038-24839B34-4061-4105-923D-A6425881FA9AQ35216441-E35243BA-CB32-481B-B276-77B126795B45Q35523534-6A7A6056-7732-44BE-A937-0E791911D819Q36111979-846678EE-F008-4B09-AD73-33E19E1EAF65Q36127286-CAFBE723-98FA-44CE-AB79-0FB582F7DC47Q36141941-86E07447-6835-419B-A537-78315593DC81Q36302882-14B6DF1F-081F-4997-9042-37A9C8C7A248Q36907742-04B8F7A2-6AEE-432D-8C59-370369552548Q36972476-EEBD0692-8741-48F3-975A-A078FDA3FF17Q37004095-8754A1B8-EF16-40EE-86C6-3CD74835E235Q37028474-18BB892D-3E60-4A2F-8985-B1A88C5E5C4DQ37390813-BA3D7C5D-0AB0-4D2D-B477-F201B5DCC734Q37414845-830C00F4-B4A4-4138-85E6-1F860F4DAD94Q37597898-065159E6-D49A-47D7-B1E9-1D0D5968F599Q37602455-A943B505-0C5C-4836-9C15-9AF3EF9B8318
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Nicolas Roche
@ast
Nicolas Roche
@en
Nicolas Roche
@es
Nicolas Roche
@nl
type
label
Nicolas Roche
@ast
Nicolas Roche
@en
Nicolas Roche
@es
Nicolas Roche
@nl
prefLabel
Nicolas Roche
@ast
Nicolas Roche
@en
Nicolas Roche
@es
Nicolas Roche
@nl
P214
P106
P21
P214
P31
P496
0000-0002-3162-5033
P734
P7859
viaf-188407453